Neovascular Age-related Macular Degeneration: Emerging Therapies With an EYE On Treatment Frequency

1.25 CME
$0 FEE
nAMD OG image size


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.  

Target Audience

The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with neovascular age-related macular degeneration.

Learning Objective

Upon successful completion of this activity, participants should be better able to:

  • Review the burden associated with the conventional use of anti-vascular endothelial growth factor (anti-VEGF) agents in the treatment of neovascular age-related macular degeneration (nAMD).
  • Assess new dosing and administration schedules for the treatment of nAMD that may reduce injection frequency while maintaining visual acuity. 
  • Analyze new evidence pertaining to the safety and efficacy of therapies in late-stage development for the management of nAMD.

Activity Chair

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV


Diana V. Do, MD
Vice Chair for Clinical Affairs
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA

Michael A. Singer, MD
Director of Clinical Research
Medical Center Ophthalmology Associates
Clinical Professor
University of Texas Health Science Center
San Antonio, TX 


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationship(s)

Diana V. Do, MD
Consulting Fee: Genentech, Kodiak, Novartis, Regeneron, Santen
Contracted Research: Genentech, Novartis, Regeneron, Santen

Arshad M. Khanani, MD, MA
Consulting Fee: Aerpio, Alimera, Allergan, Genentech, Kodiak, Notal Vision, Novartis, Opthea, Orbit Biomedical, Oxurion, PolyPhotonix, Recens Medical, Regenxbio, Roche, Santen
Speakers Bureau: Allergan, Genentech, Novartis
Contracted Research: Adverum, Aerpio, Allergan, Clearside, Gemini Therapeutics, Genentech, Gyroscope, Kodiak, Novartis, Ophthotech, Opthea, Oxurion, Regenxbio, Roche

Michael A. Singer, MD
Consulting Fee: Aerie, Allegro, Allergan, Genentech, Kodiak, Novartis, Regeneron, Santen
Speakers Bureau: Allergan, Genentech, Mallinckrodt, Novartis, Regeneron, Spark
Contracted Research: Aerie, Allegro, Allergan, Archway, Champ, DRCR, Genentech, Icon, Ionis, KalVista, Kestrel, Kodiak, Lumina, Merlin, Novartis, Opthea, Optos, Panda Wet, Regeneron, Santen, Senju, Sydnexis, Xplore, Yosemite

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA–approved or investigational use of products/devices.


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, August 28, 2019, to August 27, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the CME posttest and evaluation in their entirety. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at